Galapagos applied for the Class 2 reimbursement of a novel therapy, filgotinib, for the treatment of rheumatoid arthritis. They asked Hict for support in the pharmaco-economic section of this reimbursement submission, including the preparation and moderation of a consensus discussion on defining the target population and clinical practice.
The support included:
Hict’s approach consisted of four phases:
Phase 1 – Intake phase
The current context of rheumatoid arthritis treatment in Belgium, including reimbursement conditions of already reimbursed products and expected future products, and the strategy for the reimbursement submission of filgotinib were analyzed and discussed. Based on the information gathered on the treatment of rheumatoid arthritis and the BIA model requirements specified by the client, a high-level desk research was performed. A gap analysis matching the available data with the required data was performed.
Phase 2 – Data collection
Based on the gap-analysis the data collection protocol was validated and executed. In this phase, relevant Belgian inputs for the BIA model were collected via an expert survey followed by a consensus meeting. This phase consisted of two major subsections:
Phase 3 – BIA model support
A new, transparent, BIA model tailored to the Belgian RA clinical practice and requirements and expectations of RIZIV/INAMI was developed. After developing the BIA model, the model was populated with the data collected in previous phases, in line with the Belgian health economic guidelines, and results were generated. The model inputs and types of results to be generated were decided on in close collaboration with Galapagos.
Phase 4 – BIA model report support
A BIA report meeting the Belgian reimbursement submission guidelines and clearly describing the model, its methodology, the inputs, and the results was developed in Dutch and validated by Galapagos for finalization.